BEVERLY, MA and TORONTO, ON--(Marketwired - Nov 17, 2015) - Hamilton Thorne Ltd. (TSX VENTURE: HTL) ("Hamilton Thorne" or the "Company"), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced the hiring of Keith F. Edwards as Senior Vice President & General Manager of Hamilton Thorne, Inc., reporting to CEO and President David Wolf.
Mr. Edwards was most recently President of Biocoat, Inc. of Horsham, PA and during his five-year tenure grew sales by 117%. Edwards brings a keen knowledge of the fertility market as he led channel sales, direct to consumer marketing efforts for Biocoat's PICSI® Sperm selection device and HBA® Sperm binding assay. Mr. Edwards will be responsible for customer facing areas of Hamilton Thorne, including sales, marketing and customer support as well as regulatory affairs and production. Mr. Edwards had previously held sales, marketing and executive positions at Biomet Osteobiologics, Ansell Healthcare, and Henry Schein, Inc.
"I am excited to join Hamilton Thorne at this time of rapid innovation in the fertility clinic space, and to contribute to growing the strong Hamilton Thorne brand," noted Mr. Edwards.
David Wolf, the Company's President and CEO commented, "We are pleased to have someone with Keith's strong background in sales and marketing as well as expertise in the fertility market join our company. This is a major step in building the team that we need to support our continued growth and acquisition strategy."
The Company also announced that it has granted Mr. Edwards 400,000 stock options pursuant to the Company's incentive stock option plan. The options are exercisable at Cdn$0.22 per share, vest over four years, and expire ten years from the date of grant.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets. It provides novel solutions for Life Science that reduce cost, increase productivity, improve results and enable research breakthroughs in regenerative medicine, stem cell research and fertility markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures. Its image analysis systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses.
Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard, MIT, Yale, McGill, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, and Oxford and Cambridge.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.